Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron ...

Regeneron acquires rights to HS-20094, a promising obesity treatment from Hansoh Pharma, enhancing its metabolic programs. Quiver AI Summary. Regeneron Pharmaceuticals has entered a strategic ...

Semaglutide and similar GLP-1 drugs have proven to be highly effective obesity and type 2 diabetes treatments. But like every drug, they have their possible trade-offs, including muscle loss.

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

Regeneron highlighted that about 35% of weight loss from semaglutide alone ... Regeneron's Obesity Trial With Novo Nordisk's Wegovy ... Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially ...